ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2513

Frequency, Diagnosis, and Management of Polymyalgia Rheumatica in Germany – Database Analysis of Medical Insurance Data
Abstract Number: 1315

From Presentation to Publication: Tracking the Publication Rate of Abstracts Presented at American College of Rheumatology Convergence Conference in the Years 2015 and 2018
Abstract Number: 2453

Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study
Abstract Number: 1337

Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Abstract Number: 0578

Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
Abstract Number: 1498

Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 1025

Gender Disparities in Disease Impact and Treatment Access for Spondyloarthropathies in Latin America: Insights from a Web Survey
Abstract Number: 0571

Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
Abstract Number: 2567

Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study
Abstract Number: 2316

Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
Abstract Number: 2481

General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Abstract Number: 0922

Generation and Pathophysiological Analysis of M694I Variant Knock-in Mice of Human MEFV Gene: Insights from Single-Cell RNA Sequencing
Abstract Number: 2139

Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro
Abstract Number: 0884

Genetic Architecture Divergence in Sjögren’s Disease Subphenotypes and Populations: Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Cases in European Populations
Abstract Number: 1485

Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].